Phase 1 Trial Protocol: Tucatinib, Trastuzumab, Capecitabine with SRS for HER2+ Brain Mets

Overview

This protocol outlines a multicenter phase 1 clinical trial evaluating the safety and efficacy of combining tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery (SRS) in patients with brain metastases from HER2-positive breast cancer. The study aims to address the unmet need for effective CNS-directed therapies by integrating systemic HER2-targeted agents with precise local radiation.

Background

HER2-positive breast cancer accounts for 15-20% of breast cancer cases and is associated with aggressive disease and a high incidence of brain metastases (up to 50%). Traditional treatments like whole-brain radiation therapy have limited survival benefits and cause neurocognitive decline, making stereotactic radiosurgery (SRS) the preferred local treatment for limited brain metastases. However, SRS alone cannot prevent new brain lesions due to microscopic disease. Tucatinib, a HER2-selective tyrosine kinase inhibitor, combined with trastuzumab and capecitabine, has demonstrated CNS activity and improved progression-free and overall survival in metastatic HER2-positive breast cancer patients, but its safety and efficacy combined with SRS remain untested.

Data Highlights

Key Findings

• HER2-positive breast cancer frequently metastasizes to the brain, with up to 50% of patients developing brain metastases during disease progression.
• SRS is effective for local control of limited brain metastases but does not prevent new lesions due to microscopic disease spread.
• Tucatinib combined with trastuzumab and capecitabine improves intracranial progression-free survival and overall survival compared to placebo in HER2-positive metastatic breast cancer patients with brain metastases.
• The HER2CLIMB trial demonstrated a CNS objective response rate of 42% with this triplet regimen and led to its regulatory approval.
• The safety and efficacy of combining tucatinib-based systemic therapy with SRS have not been previously evaluated, representing a significant knowledge gap.
• The current phase 1 trial aims to assess this combination to potentially improve outcomes by addressing both macroscopic and microscopic CNS disease.

Clinical Implications

Combining tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery may offer a promising strategy to improve intracranial disease control in patients with HER2-positive breast cancer brain metastases. This approach targets both visible lesions with SRS and microscopic disease with systemic therapy, potentially delaying CNS progression and preserving neurocognitive function. Pending safety and efficacy data from this trial, this combination could become a new standard for managing brain metastases in this population.

Conclusion

This phase 1 trial protocol addresses an important unmet need by evaluating the integration of effective systemic HER2-targeted therapy with precise local radiation in HER2-positive breast cancer brain metastases. The results may establish a novel combined modality approach to improve CNS outcomes and survival.

References

1. Siegel et al. 2020 -- Cancer statistics, 2020
2. Slamon et al. 1987 -- HER2 in breast cancer
3. Lin et al. 2008 -- CNS metastases in HER2+ breast cancer
4. NCCN Guidelines 2023 -- Breast Cancer
5. Bachelot et al. 2013 -- Brain metastases in breast cancer
6. Niikura et al. 2014 -- CNS sanctuary in HER2+ breast cancer
7. Le Scodan et al. 2012 -- Survival in HER2+ brain metastases
8. Chang et al. 2009 -- Neurocognitive effects of WBRT
9. Lagerwaard et al. 2008 -- SRS for brain metastases
10. Minniti et al. 2014 -- CNS relapse post-SRS
11. Niwińska et al. 2010 -- Systemic therapy for brain mets
12. Lockman et al. 2010 -- BBB and drug penetration
13. Murthy et al. 2020 -- Tucatinib CNS activity
14. Krop et al. 2017 -- Capecitabine in brain metastases
15. Swain et al. 2020 -- Trastuzumab efficacy
16. Cortés et al. 2022 -- DESTINY-Breast12 trial
17. Yarden & Sliwkowski 2001 -- HER family biology
18. Hynes & Lane 2005 -- HER2 signaling pathways
19. Freeman et al. 2019 -- Tucatinib mechanism
20. Mackey et al. 2016 -- Capecitabine pharmacology
21. Hudis 2007 -- Trastuzumab mechanism
22. Murthy et al. 2020 -- Phase 1b tucatinib study
23. Murthy et al. 2020 -- HER2CLIMB trial results
24. Murthy et al. 2021 -- HER2CLIMB CNS outcomes